|
|||||
|
|
||||||
Journal of Clinical Oncology, Vol 24, No 24 (August 20), 2006: pp. 4041a-4042 © 2006 American Society of Clinical Oncology. DOI: 10.1200/JCO.2006.07.3155
In ReplyInstitute of Hematology and Oncology "Seràgnoli", University of Bologna, Bologna, Italy
Department of Biomedical Sciences and Human Oncology, Section of Dermatology, University of Turin, Turin, Italy
Department of Dermatological Sciences, University of Florence, Florence, Italy
Department of Dermatology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Maggiore of Milan and University of Milan-Bicocca, Milan, Italy
Institute of Dermatology "Immacolata", Rome, Italy
University of Ancona, Ancona, Italy
Dipartimento Biotecnologie Cellulari ed Ematologia, University "La Sapienza", Rome, Italy
Unit of Dermatology, University of Padua, Padua, Italy
University of Pavia, Pavia, Italy
"Tor Vergata" University, Rome, Italy
University of Florence, Florence, Italy
Institute of Hematology and Oncology "Seràgnoli", University of Bologna, Bologna, Italy
Department of Biomedical Sciences and Human Oncology, Section of Dermatology, University of Turin, Turin, Italy
Department of Genetics, Biology and Medical Chemistry, Section of Medical Statistics, University of Turin, Turin, Italy
Institute of Dermatology, University of Bologna, Bologna, Italy
Department of Hematology, Ospedale Maggiore and University of Milano, Milan, Italy
Anatomic Patology Section, Department of Human Pathology, University of Pavia and IRCCS Policlinico S. Matteo, Pavia, Italy
Institute of Hematology and Oncology "Seràgnoli", University of Bologna, Bologna, Italy
Department of Human Pathology and Oncology, University of Florence, Italy
Department of Biomedical Sciences and Human Oncology, Section of Dermatology, University of Turin, Turin, Italy We received with great interest the comments from Drs Wilson and Smith. We thank them for the punctual referencing of the article from Grange et al, published in the Journal of Clinical Oncology in 2001.1 In fact, the latter represents a milestone in the appropriate classification of large cell cutaneous B-cell lymphoma (CBCL), now fully established in the consensus WHO-European Organisation for Research and Treatment of Cancer classification of primary cutaneous lymphomas.2 However, the nosological dignity of CBCL characterized by de novo diffuse large round cell infiltration was already suggested and supported in the article published by the French group in 1999.3 Regarding the nice and interesting article published by Smith et al4 in the Journal of Clinical Oncology in 2005, which concerns a large series of nearly 1,000 patients, it is noteworthy to emphasize that it is based on data from Surveillance, Epidemiology and End Results registry. Although this study is of overall great epidemiologic value and suggests a temptative way of combining different features for the final prognostic evaluation (prognostic index), its resultsclaiming over 400 patients with diffuse large CBCL, which account for approximately 40% of the totalare possibly biased by a definition which is not necessarily adherent to that now clearly stated in the consensus WHO-European Organisation for Research and Treatment of Cancer classification (ie, diffuse infiltration by round, noncleaved cells, heavily expressing bcl-2 and MUM-1, and genetically characterized by an activated B-cell profile.) In our study, although a centralized histologic revision was not performed, the pathologists from each participating center were asked to review their cases strictly following the criteria which currently allow to them to separate diffuse large B-cell lymphoma, leg-type from follicular lymphoma patients with a diffuse large (cleaved) cell predominance. This method appears as substantially different from that followed by Smith et al4 in their study. However, there is no doubt that this latter has added an interesting piece of work to the diagnosis, classification, prognostic evaluation, and proper treatment planning of primary CBCL. Authors' Disclosures of Potential Conflicts of Interest The authors indicated no potential conflicts of interest. ACKNOWLEDGMENTS This study was supported in part by Sezione di Bologna dellAssociazione Italiana contro Leucemie, Linfomi e Mielomi (BolognAIL). REFERENCES
1. Grange F, Bekkenk MW, Wechsler J, et al: Prognostic factors in primary cutaneous large B-cell lymphomas: A European multicenter study. J Clin Oncol 19:3602-3610, 2001 2. Willemze R, Jaffe E, Burg G, al: WHO-EORTC classification of cutaneous lymphomas. Blood 105:3768-3785, 2005 3. Grange F, Hedelin G, Joly P, et al: Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome: The French Study Group on Cutaneous Lymphomas. Blood 93:3637-3642, 1999 4. Smith BD, Smith GL, Cooper DL, et al: The cutaneous B-cell lymphoma prognostic index: A novel prognostic index derived from a population-based registry. J Clin Oncol 23:7246-7248, 2005
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|